Long-term results of Ahmed valve implantation in refractory pediatric uveitic glaucoma
Purpose
To evaluate the effectiveness and safety of Ahmed valve implantation in children with refractory uveitic glaucoma (UG).
Methods
Ahmed valve implantation was performed in 11 children aged from 7 to 17 years (10 eyes) with open-angle or combined form of UG uncompensated on maximum hypotensive regime. Previously all patients underwent on average 2.1 ± 0.9 hypotensive surgeries (predominantly trabeculectomy). 7 eyes were pseudophakic, 2 phakic, 2 aphakic. IOP at the time of surgery was on average 30.5 ± 4.4 mm Hg. Follow-up period ranged from 18 to 40 months (on average 28.9 ± 9.1).
Results
Compensation for glaucoma was achieved in 91% cases, among them 3 patients without and 7 patients on hypotensive therapy. Average number of hypotensive drugs after surgery was 1.7 ± 1.5, which was significantly less than before surgery (p = 0.028). At the end of the observation period average IOP was 18.1 ± 5.3 mm Hg (significantly lower than preoperative, p = 0.008). During the surgery in 1 patient mild bleeding from the vessels of the anterior chamber angle after paracentesis was observed. In other cases intervention and postoperative period were uncomplicated.
Conclusion
Ahmed valve implantation is an effective and safe method for the surgical treatment of refractory UG in children and can be recommended, if previous antiglaucomatous operations are ineffective.
Conflict of interest
No
Authors 1
Last name
DENISOVA
Initials of first name(s)
E
Department
Helmholtz National Medical Research Center of Eye Diseases
City
Moscow
Country
Russian Federation
Authors 2
Last name
Katargina
Initials of first name(s)
L
Department
Helmholtz National Medical Research Center of Eye Diseases
City
Moscow
Country
Russian Federation
Authors 3
Last name
Ibaid
Initials of first name(s)
B
Department
Helmholtz National Medical Research Center of Eye Diseases
City
Moscow
Country
Russian Federation
Authors 4
Last name
Khrabrova
Initials of first name(s)
M
Department
Helmholtz National Medical Research Center of Eye Diseases
City
Moscow
Country
Russian Federation
This website uses cookies to ensure you get the best experience on our website.
Learn more